Patent intelligence · US
US 11992472
Compositions and methods for enhancing the efficacy of contraceptive microbicides
Compositions and methods for enhancing the efficacy of contraceptive microbicides
Patent details — US 11992472
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2024
- Expiration
- May 23, 2044
- Applicant
- Evofem, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/19, A61K31/675, A61K47/10
Quick answer
US 11992472 (Compositions and methods for enhancing the efficacy of contraceptive microbicides) is held by Evofem, Inc.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Evofem, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/19, A61K31/675, A61K47/10, A61K47/12, A61K47/36
More from Evofem, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12280037
Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
granted -
US 12172969
Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof
granted -
US 11439610
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 11419835
Method of treatment and prevention of bacterial vaginosis
granted -
US 11337989
Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
granted -
US 10568855
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 9566232
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted
Frequently asked questions
What is US patent 11992472?
US 11992472 (Compositions and methods for enhancing the efficacy of contraceptive microbicides) is held by Evofem, Inc.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11992472?
Evofem, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 11992472 expire?
Our index shows an expiration date of May 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.